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Abstract
We have investigated the actions of the PLC inhibitor, U73122, and its close analogue, U73343, which does not inhibit
w 2qxPLC, in Fura-2-loaded human platelets. Rises in Ca evoked by thrombin and collagen, and the TxA -dependent rise ini 2
w 2qxCa evoked by thapsigargin, were abolished by U73122, indicating that it inhibits the activity of both b and g isoformsi
of PLC. The supposed control compound, U73343, was found to inhibit TxA formation; it therefore partially inhibited the2
w 2qxrise in Ca evoked by low concentrations of thrombin, by thapsigargin or by collagen. U73343 had a greater effect thani
aspirin on the action of collagen, indicating an action on the TxA -independent component of the signal, via PLC .2 g 2
U73343 lowered TxA production by inhibiting the activation of cPLA , probably at a tyrosine phosphorylation step.2 2
U73343 seems to inhibit only the tyrosine kinases involved in the activation of PLC and the generation of TxA . Ing 2
contrast, U73122 increased tyrosine phosphorylation of platelet proteins, perhaps by inhibiting receptor-independent
tyrosine phosphatases, but inhibited all further tyrosine phosphorylation on addition of thrombin or other agonists.
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1. Introduction
w xThe PLC inhibitor, U73122 1 , has been used in a
number of studies of calcium signalling mechanisms
w x w x2–4 and other PLC-dependent processes 5 . The
structural analogue of U73122, U73343, which has
w 2q xAbbreviations: Ca , cytosolic calcium concentration;i
 .cPLA , cytosolic phospholipase A ; Hepes, 4- 2-hydroxyethyl -2 2
1-piperazine-ethanesulfonic acid; PLC, phospholipase C; U73122,
w ww .  . x x1- 6- 17beta -3-methoxyestra-1,3,5 10 -trien-17-yl -amino -
x . w ww .hexyl - 1H-pyrrole-2, 5-dione; U73343, 1- 6- 17beta -3-
 . x x xmethoxyestra-1,3,5 10 -trien-17-yl amino hexyl -2,5-pyrrolidine-
dione; TxA , thromboxane A ; TxB , thromboxane B2 2 2 2
) Corresponding author. Fax: q44 01223 333840; e-mail:
sos10@cus.cam.ac.uk.
w xnegligible activity as a PLC inhibitor 1 , has been
w xused as a control compound 1–5 .
In a study of the effects of U73122 and U73343 on
platelet aggregation, we found that U73343 was a
potent inhibitor of the responses evoked by collagen
and the inhibitor of the Ca2q store Ca2q-ATPase,
w xthapsigargin 6 . This inhibition occurred upstream of
the activation of cPLA .2
We have now investigated the effects of U73122
and U73343 on platelet Ca2q signalling evoked by
thrombin, collagen and thapsigargin. Thrombin ele-
w 2qxvates Ca predominantly via PLC isoforms, buti b
w xmay also recruit isoforms of PLC 7–9 . The colla-g
gen-evoked Ca2q signal is generated most directly
w xvia activation of PLC 10 , but also relies ong 2
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secondary effects of TxA generation. TxA acts to2 2
w 2qx w xelevate Ca via activation of PLC 11 . Thapsi-i b 1
w 2qxgargin acts to increase Ca by inhibition of thei
Ca2q-ATPase activity of the intracellular Ca2q store
w x  w x.12 and without activation of PLC e.g. 13 . In
platelets, however, the thapsigargin-evoked rise in
w 2qxCa is considerably increased by its ability toi
stimulate the formation of TxA , which releases2
2q  .Ca from a store sensitive to Ins 1,4,5 P but insen-3
w xsitive to thapsigargin 13,14 .
Using this combination of agonists, we show that
both U73122 and U73343 affect Ca2q signalling in
human platelets; that U73122 inhibits both PLC andb
PLC isoforms; that the effects of U73343 are mainlyg
or entirely secondary to inhibition of TxA genera-2
tion and that both U73122 and U73343 affect platelet
protein tyrosine phosphorylation so cautioning their
use in Ca2q signalling studies.
2. Materials and methods
2.1. Platelet preparation and aggregation
Fura-2-loaded human platelets were prepared es-
w xsentially as previously described 15 . Briefly, cit-
rated platelet-rich plasma was incubated with 3 mM
Fura-2rAM for 45 min at 378C. The cells were then
collected by centrifugation and resuspended at a den-
sity of 1.0=108rml in Hepes-buffered saline con-
 .taining in mM : 145 NaCl, 10 Hepes, 10 glucose, 5
KCl, 1 MgSO , pH 7.45 and supplemented with4
0.1% wrv bovine serum albumin and 20 mgrml
apyrase. Where required, aspirinated platelets were
prepared by addition of 200 mM aspirin to citrated
platelet-rich plasma prior to Fura-2 loading.
Platelet aggregation was monitored in a Chronolog
 .Havertown, PA., USA aggregometer at 378C under
w xstirring at 900 rpm 16 .
[ 2q]2.2. Measurement of Ca i
w 2qxCa was determined in Fura-2-loaded plateletsi
 8 .1=10 rml under slow stirring at 378C by dual
w xwavelength fluorometry, as previously described 17 .
2.3. Measurement of TxB2
TxA production was quantified as its product2
TxB in platelet-free supernatants, centrifuged from2
suspensions activated under stirring, using a kit from
 .DuPont Boston, MA, USA as previously described
w x16 .
2.4. Protein tyrosine phosphorylation
Protein tyrosine phosphorylation was detected by
gel electrophoresis and Western blotting with a spe-
 .cific antiphosphotyrosine antibody 4G10 as previ-
w xously described 15 .
2.5. Preparation and assessment of U73122 and
U73343
Stocks of U73122 and U73343 were always freshly
prepared in dry DMSO. Since the activity of both
compounds was variable from batch to batch, experi-
ments were preceded by an aggregation dose-re-
 .sponse study not shown . U73122 and U73343 had
an inhibitory effect on collagen-induced platelet ag-
 8 .gregation washed suspensions, 10 plateletsrml
with IC values of 1–3 mM and 10–12.5 mM,50
respectively. Higher IC values for both compounds50
were found if the platelet density was increased.
Similar cytocrit-dependent effects have been reported
w xby others 18 . Hence comparing use of these com-
pounds at different concentrations within and be-
tween studies is difficult. To avoid possible cytotoxic
and additional side effects, all our experiments were
conducted using concentrations of U73122 or U73343
at approximately twice the IC value for collagen-50
evoked aggregation, determined as described above.
At these concentrations, basal levels of platelet
w 2qxCa were not increased, indicating an absence ofi
platelet activating or lytic effects.
2.6. Materials
U73122 and U73343 were from Biomol Plymouth
.Meeting, PA, U.S.A . Apyrase and sodium arachi-
 .donate were from Sigma St. Louis, MO, U.S.A .
3. Results
3.1. Effects of U73122 and U73343 on agonist-e˝oked
[ 2q]rises in Ca and TxA production in plateleti 2
suspensions
 .  .The effects of U73343 20 mM , U73122 5 mM
 . w 2qxand aspirin 200 mM on the rises in Ca evokedi
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w 2qx  .Fig. 1. Effects of U73343, U73122 and aspirin on thrombin-evoked rises in Ca in Fura-2-loaded platelets. Thrombin 10 nM addedi
2q  .  .as indicated to stirred platelet suspensions in presence of 1 mM external Ca . Platelets were either A untreated, or pretreated with B
 .  .20 mM U73343, C 5 mM U73122 or D 200 mM aspirin. U73343 or U73122 were added to suspensions 3 min before agonist addition.
Aspirin was added to platelet-rich plasma during fura-2-loading.
w 2qx  .Fig. 2. Effects of U73343, U73122 and aspirin on thapsigargin-evoked rises in Ca in Fura-2-loaded platelets. Thapsigargin 100 nMi
2q  .added as indicated to stirred platelet suspensions in presence of 1 mM external Ca . Platelets were either A untreated, or pretreated
 .  .  .with B 20 mM U73343, C 5 mM U73122 or D 200 mM aspirin as for Figs. 1.
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 .in platelets in suspension by thrombin 10 nM ,
 .  .thapsigargin 100 nM or collagen 5 mgrml are
shown in Fig. 3. U73343 had a small inhibitory effect
w 2qx on the thrombin-evoked rise in Ca which wasi
.reduced to 86"6% of control; mean"S.E., ns4
 .Fig. 1B . The effect of U73343 was similar to that of
 .aspirin Fig. 1D and may thus be attributed to re-
duced formation of TxA . TxB levels 5 min after2 2
activation were 383 ngr108 platelets under control
conditions and 180 ngr108 platelets after treatment
with U73343. U73343 did not reduce the thrombin-
w 2qx evoked rise in Ca in aspirin-treated cells noti
.shown . U73122 essentially abolished the thrombin-
w 2qx  .evoked rise in Ca 5"1%; Fig. 1C and TxBi 2
production was reduced to only 21 ngr108 platelets
after 5 min of activation.
w 2qxU73343 substantially reduced the rise in Ca i
evoked by thapsigargin to 23"3% of control; mean
.  ."S.E., ns4 Fig. 2B . This effect was mimicked
 .by aspirin 25"1%; Fig. 2D . U73343, like aspirin,
essentially abolished thapsigargin-evoked TxA pro-2
duction. 5 min after thapsigargin addition, TxB pro-2
duction was 402 ngr108 platelets under control con-
ditions and 6 ngr108 platelets in the presence of
U73343. U73122 also inhibited the thapsigargin-
w 2qx  .evoked rise in Ca 32"3%; Fig. 2C and TxBi 2
production was reduced to just 14 ngr108 platelets 5
min after activation.
 .  .Both U73343 Fig. 3B and U73122 Fig. 3C
w 2qxessentially abolished the rise in Ca evoked byi
w 2qxcollagen. The collagen-evoked rise in Ca wasi
 .reduced to 7"3% mean"S.E., ns4 of control in
the presence of U73343 and 0.4"0.4% mean"
.S.E., ns4 in the presence of U73122. Formation of
TxB 5 min after collagen addition was 233 ngr1082
platelets under control conditions and just 24 and 8
ngr108 platelets after treatment with U73343 or
U73122, respectively. The effects of both compounds
 .were greater than that of aspirin Fig. 3D , which
w 2qx reduced peak Ca to 20"7% mean"S.E., nsi
.4 of control.
 .As shown in Fig. 4, U73343 20 mM had only a
w 2qxmarginal inhibitory effect on the rise in Ca i
 .evoked by arachidonic acid 15 mM . In contrast, the
w 2qx  .Fig. 3. Effects of U73343, U73122 and aspirin on collagen-evoked rises in Ca in Fura-2-loaded platelets. Collagen 5 mgrml addedi
2q  .  .as indicated to stirred platelet suspensions in presence of 1 mM external Ca . Platelets were either A untreated, or pretreated with B
 .  .20 mM U73343, C 5 mM U73122 or D 200 mM aspirin as for Fig. 1.
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w 2q xFig. 4. Effects of U73343, U73122 and aspirin on rises in Ca i
evoked by arachidonic acid in Fura-2-loaded platelets. Sodium
 .arachidonate 15 mM added to stirred platelet suspensions in
presence of 1 mM external Ca2q. Platelets were either untreated
 .control , or pretreated with 5 mM U73122, 20 mM U73343, or
200 mM aspirin as for Fig. 1. Bars indicate mean"S.E.M. of 4
experiments.
arachidonic acid-evoked response was essentially
 . abolished by U73122 5 mM or by aspirin 200
.mM .
Fig. 5. Effects of U73122 on protein-tyrosine phosphorylation
evoked by thrombin. Samples of platelet suspension treated and
activated as described for Fig. 1 were withdrawn from the
 .fluorimeter cuvette 15 s before y15 or 15, 30 or 45 s after
 .thrombin 10 nM addition and processed as described in Section
2. Gels show phosphoproteins from control platelets treated with
.  .DMSO vehicle alone lefthand side and from platelets pre-
 .treated for 3 min with 5 mM U73122 righthand side . Molecular
 .  .size calibrated using Rainbow Markers Amersham of size kDA
indicated on right of gels.
3.2. Effects of U73122 on protein tyrosine phosphory-
lation
 .Thrombin 10 nM evoked a substantial increase in
protein tyrosine phosphorylation, which was most
marked at substrates of 70 kDa and 130 kDa but also
 .apparent at several bands between these Fig. 5 .
 .U73122 10 mM itself increased protein tyrosine
phosphorylation at a number of substrates, including
some not affected by activation of the cells with
 .  .thrombin Fig. 5 or collagen not shown .
Thrombin-evoked changes in protein-tyrosine phos-
phorylation were completely abolished by U73122,
 .and in similar experiments with collagen 5 mgrml
 .the same abolition was observed not shown .
4. Discussion
4.1. Effects of U73122 on agonist-e˝oked rises in
[ 2q]Ca i
Although some reports have concluded that
U73122 is a relatively specific inhibitor of G-protein
w xactivated PLC isoforms 2 , other authors report in-
hibitory effects of this compound on responses evoked
by EGF and PDGF, consistent with inhibition of
w xPLC isoforms as well 19–22 . Human plateletsg
w xcontain both PLC and PLC isoforms 23,24 andb g
our data confirm that activation of both is inhibited
by U73122.
w 2qxThe rise in Ca evoked by thapsigargin isi
w xdependent in part on the generation of TxA 13,14 .2
TxA acts via the TxA rPGH receptor which2 2 2
w xspecifically stimulates PLC 11 . The demonstratedb 1
w 2qxreduction in the thapsigargin-evoked rise in Ca i
in the presence of U73122 is thus as would be
expected when TxA -evoked PLC activity is inhib-2 b 1
w 2qxited. Similarly, we have shown that the rise in Ca i
evoked by arachidonic acid which is converted to
.TxA is abolished by U73122. However, our mea-2
surements of TxB production indicate that the action2
of U73122 on the thapsigargin-evoked response may
result more from the inhibition of TxA production2
than from the inhibition of its action.
w 2qxA substantial proportion of the elevation in Ca i
evoked by collagen is dependent upon the generation
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of TxA , however a component of the response is not2
abolished by aspirin treatment and must result from a
more direct effect of the agonist. This is via the
w xactivation of PLC 10,25 . The complete abolitiong 2
w 2qxof the collagen evoked rise in Ca by U73122i
thus indicates that this compound inhibits activation
of PLC in platelets.g 2
The effects of thrombin exerted through activation
of PLC isoforms is supplemented by effects viab
w x w xPLC 9 or PLC 8 . The complete abolition ofg1 g 2
w 2qxthe thrombin-evoked rise in Ca by U73122 isi
thus consistent with inhibition of activation of both
PLC and PLC isoforms.b g
4.2. Effects of U73343 on agonist-e˝oked rises in
[ 2q]Ca and TxA productioni 2
U73343 is frequently used as a control compound
w xfor U73122 2–5 , since it has minimal inhibitory
w xeffects on PLC 1 . However, we have previously
reported that the use of U73343 in platelets is poten-
tially complicated by the fact that this compound
inhibits the activation of cPLA and so reduces2
w xarachidonic acid release and TxA production 6 .2
That the effect of U73343 is predominantly on
arachidonic acid release, rather than its conversion to
TxA or the action of this eicosanoid, is confirmed2
here by the relatively small effect of U73343 on the
w 2qxelevation in Ca evoked by arachidonic acid. Thei
w 2qxsmall effect of U73343 on the rise in Ca evokedi
by thrombin can be explained by the demonstrated
reduced formation of TxA , a platelet metabolite that2
reinforces the thrombin-evoked signal. However, the
w 2qxmajority of the thrombin-evoked rise in Ca isi
dependent on a direct activation of PLC and this
signal would thus be expected to be unaffected by
U73343. Accordingly, U73343 was found to have no
effect on the thrombin-evoked Ca2q signal in
aspirin-treated cells.
Similarly, inhibition of the thapsigargin-evoked rise
w 2qxin Ca by U73343 can be explained by its inhibi-i
tion of TxA production since the generation of this2
autocoid contributes substantially to the
2q w xthapsigargin-evoked Ca signal in platelets 13,14 .
w 2qxThe collagen-evoked rise in Ca was com-i
pletely inhibited by U73343. Part of this effect can be
ascribed to the inhibition of cPLA activation and2
thus inhibition of collagen-evoked TxA formation2
w xas reported previously 6 . However, U73343 must
also inhibit the TxA -independent component of the2
collagen response, believed to be mediated by PLCg 2
w x10 . We have previously reported that U73343 is an
effective inhibitor of tyrosine kinase activity evoked
w xby collagen and thapsigargin 6 . The protein tyrosine
phosphorylation of a number of substrates was re-
duced by U73343 and it is possible that PLC ,g 2
which is activated by phosphorylation at tyrosine
w xresidues 26,27 , is among these.
Our data show that U73343 is not an inactive
compound in platelets and that it has effects which
interfere with intracellular signalling. Other reported
actions of U73343 include a direct inhibition of
2q w xstore-regulated Ca entry in hepatocytes 28 and
block of L-type voltage-operated Ca2q channels in
w xvascular smooth muscle 29 . There is evidence that
protein tyrosine phosphorylation plays a role in
2q w xstore-regulated Ca entry in platelets 15,30–33
w xand other cells 34–36 . The reported inhibition of
Ca2q entry by U73343 may be due to effects of this
 .compound on tyrosine kinase activity see below .
4.3. Effects of U73122 on protein tyrosine phosphory-
lation
We have previously reported that U73343 is an
inhibitor of protein tyrosine phosphorylation evoked
by collagen, thapsigargin and, to a lesser extent,
w xthrombin 6 . We have suggested that this inhibition
of tyrosine kinase activity may account for the inhibi-
tion of agonist-evoked arachidonic acid release by
U73343, with this compound inhibiting cPLA acti-2
vation at a tyrosine phosphorylation step. Here we
have demonstrated that U73343, as a consequence of
reduced cPLA activation, inhibits agonist-evoked2
TxA production which in turn affects agonist-evoked2
Ca2q signals. Reduced TxA production was associ-2
ated with some reduction in the thrombin-evoked rise
w 2qxin Ca . More strikingly, TxA production evokedi 2
by collagen or thapsigargin was almost completely
w 2qxabolished by U73343 and the rises in Ca evokedi
by these agonists were substantially suppressed.
Here we have shown that U73122 is an effective
inhibitor of tyrosine phosphorylation evoked by
thrombin and collagen. Much of this inhibition may
be explained by abolition of the agonist-evoked rise
w 2qx 2qin Ca , so preventing the Ca -dependent activa-i
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w xtion of certain tyrosine kinases 30 . However, we
have previously shown that some platelet proteins are
phosphorylated at tyrosine residues in the absence of
w 2qx 2qa rise in Ca , for example when Ca stores arei
w 2qxdepleted using thapsigargin but a rise in Ca isi
prevented by heavy buffering with the chelator,
w xBAPTA 31 . Thus the abolition of agonist-evoked
changes in protein tyrosine phosphorylation by
U73122 are consistent with this compound, like
w xU73343 6 , having a direct effect on agonist-evoked
tyrosine kinase activation.
U73122 itself affected platelet protein tyrosine
phosphorylation, promoting the phosphorylation of a
number of substrates. These included proteins which
show agonist-evoked phosphorylation e.g. 70 and
. 130 kDa and others which do not e.g., 38 and
.100–125 kDa . These effects of U73122 might be
due to activation of tyrosine kinases, inhibition of
tyrosine phosphatases, or a combination of both; the
consequence of either event renders platelet tyrosine
kinases insensitive to further stimulation by collagen,
thrombin or thapsigargin.
The present results indicate that U73122 cannot be
considered a selective inhibitor of PLC in platelets.
Other reported non-specific actions of U73122 in-
clude inhibition of phosphatidylinositol 4-kinase and
phosphatidylinositol 4-phosphate 5-kinase in platelets
w x 2q37 , inhibition of the endomembrane Ca -ATPase
w xin pancreatic acinar cells and liver microsomes 38,39
and, like U73343, direct inhibition of store-regulated
2q w xCa entry in hepatocytes 28 and block of L-type
voltage-operated Ca2q channels in vascular smooth
w xmuscle 29 .
In conclusion, our results indicate that both U73122
and U73343 have effects on protein tyrosine phos-
phorylation in platelets which mean these compounds
interfere with signalling events other than those de-
pendent on PLC.
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